The comprehensive computational framework bridges generative deep-learning models with high-throughput experimental workflows to address structural bottlenecks in biopharmaceutical development, cutting early-stage discovery and optimisation timelines from years to under two months
Traditional antibody drug discovery campaigns are hindered by high late-stage attrition rates created by unfavourable biophysical liabilities or restricted diversity within natural immune repertoires.
To help mitigate these risks, the integrated platform deployed by Creative Biolabs embeds structural predictors with transformer-based language models to optimise drug design parameters in silico prior to wet-lab asset deployment.
An essential component of this technological rollout is the AI-driven de novo antibody sequence generation service. This generative framework engineers specific, potent binders from basic structural principles without relying on natural immunisation templates or germline frameworks.
The utilisation of custom Transformer and ProteinMPNN architectures enables the platform to sample billions of unique sequence combinations, predicting optimal complementarity-determining region (CDR) loop architectures with atomic accuracy.
This capability is transformative for previously intractable or “hard-to-drug” multi-pass membrane targets such as G-protein coupled receptors (GPCRs). Case data from early biopharma adopters suggests an average 75% increase in lead generation efficiency and a 60% reduction in early-stage development costs.
A spokesperson for Creative Biolabs said, “Our integration of deep learning architectures like ProteinMPNN and AntiBERTa allows us to explore functional sequence spaces far exceeding the physical constraints of traditional phage display libraries. We are effectively transitioning biotherapeutic R&D from retrospective empirical screening to prospective, data-driven multi-objective optimisation.”
Complementing de novo design, Creative Biolabs’ AI-driven antibody engineering service addresses downstream developability and immunogenicity profiles.
By using Graph Convolutional Networks (GCNs) and molecular dynamics simulations to map precise epitope-paratope interfaces, the platform executes high-precision affinity maturation to achieve sub-nanomolar binding kinetics.
At the same time, CamSol- and TAP-inspired heuristics screen variants for biophysical liabilities, identifying self-interaction, charge asymmetry, and aggregation risks early to ensure seamless integration with scalable biomanufacturing requirements.
The industry impact of this closed-loop system has been validated by biopharma innovators with a verified customer review from a US-based director of Antibody Engineering stating, “The AI-based pre-screening pipeline from Creative Biolabs significantly reduced our experimental workload and turnaround time. We achieved higher-quality antibody hits with stronger binding profiles, saving both time and budget across our early discovery program.”
To aid research teams in navigating the complexities of modern machine-learning models in biology, Creative Biolabs has outlined the baseline capabilities addressing common computational constraints:
- Statistical Expansion of Sequence Diversity: Instead of enlarging physical library volumes, generative algorithms learn structural motifs from millions of open-source sequences to generate novel clusters under strict germline and liability constraints.
- Discovery Under Low-Structure Informational Conditions: When high-resolution experimental structures of target antigens are unavailable, the platform executes sequence-based embeddings and deep homology modelling to predict compatible paratope patterns, sustaining active discovery lines.
